These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 18508689)

  • 21. Regulation of Toll-like receptor signaling pathways in innate immune responses.
    Qian C; Cao X
    Ann N Y Acad Sci; 2013 Apr; 1283():67-74. PubMed ID: 23163321
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TLR signaling.
    Kawai T; Akira S
    Semin Immunol; 2007 Feb; 19(1):24-32. PubMed ID: 17275323
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased cytokine response after toll-like receptor stimulation in patients with stable coronary artery disease.
    Elsenberg EH; Sels JE; Hillaert MA; Schoneveld AH; van den Dungen NA; van Holten TC; Roest M; Jukema JW; van Zonneveld AJ; de Groot PG; Pijls N; Pasterkamp G; Hoefer IE
    Atherosclerosis; 2013 Dec; 231(2):346-51. PubMed ID: 24267249
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of toll-like receptor and cytokine signaling--a unifying theme in ischemic tolerance.
    Karikó K; Weissman D; Welsh FA
    J Cereb Blood Flow Metab; 2004 Nov; 24(11):1288-304. PubMed ID: 15545925
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monocyte toll-like receptor 2 and 4 responses and expression following percutaneous coronary intervention: association with lesion stenosis and fractional flow reserve.
    Versteeg D; Hoefer IE; Schoneveld AH; de Kleijn DP; Busser E; Strijder C; Emons M; Stella PR; Doevendans PA; Pasterkamp G
    Heart; 2008 Jun; 94(6):770-6. PubMed ID: 17686802
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Toll-like receptor 2 and 4 stimulation elicits an enhanced inflammatory response in human obese patients with atherosclerosis.
    Scholtes VP; Versteeg D; de Vries JP; Hoefer IE; Schoneveld AH; Stella PR; Doevendans PA; van Keulen KJ; de Kleijn DP; Moll FL; Pasterkamp G
    Clin Sci (Lond); 2011 Sep; 121(5):205-14. PubMed ID: 21446916
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Toll-like Receptors in the Vascular System: Sensing the Dangers Within.
    Goulopoulou S; McCarthy CG; Webb RC
    Pharmacol Rev; 2016 Jan; 68(1):142-67. PubMed ID: 26721702
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monocytes in coronary artery disease and atherosclerosis: where are we now?
    Ghattas A; Griffiths HR; Devitt A; Lip GY; Shantsila E
    J Am Coll Cardiol; 2013 Oct; 62(17):1541-51. PubMed ID: 23973684
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Toll-like receptor signaling in liver ischemia and reperfusion.
    Chang WJ; Toledo-Pereyra LH
    J Invest Surg; 2012 Aug; 25(4):271-7. PubMed ID: 22853814
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TLR signaling: an emerging bridge from innate immunity to atherogenesis.
    Michelsen KS; Doherty TM; Shah PK; Arditi M
    J Immunol; 2004 Nov; 173(10):5901-7. PubMed ID: 15528321
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epicardial adipocyte hypertrophy: Association with M1-polarization and toll-like receptor pathways in coronary artery disease patients.
    Vianello E; Dozio E; Arnaboldi F; Marazzi MG; Martinelli C; Lamont J; Tacchini L; Sigrüner A; Schmitz G; Corsi Romanelli MM
    Nutr Metab Cardiovasc Dis; 2016 Mar; 26(3):246-53. PubMed ID: 26841679
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interactions of oral pathogens with toll-like receptors: possible role in atherosclerosis.
    Hajishengallis G; Sharma A; Russell MW; Genco RJ
    Ann Periodontol; 2002 Dec; 7(1):72-8. PubMed ID: 16013219
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Colchicine in ischemic heart disease: the good, the bad and the ugly.
    D'Amario D; Cappetta D; Cappannoli L; Princi G; Migliaro S; Diana G; Chouchane K; Borovac JA; Restivo A; Arcudi A; De Angelis A; Vergallo R; Montone RA; Galli M; Liuzzo G; Crea F
    Clin Res Cardiol; 2021 Oct; 110(10):1531-1542. PubMed ID: 33713178
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Toll-like receptor signaling and atherosclerosis.
    Michelsen KS; Arditi M
    Curr Opin Hematol; 2006 May; 13(3):163-8. PubMed ID: 16567960
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Role of the infection and inflammation in atherosclerosis development (literature review)].
    Arshinov AB; Maslova IG
    Angiol Sosud Khir; 2010; 17(1):35-41. PubMed ID: 21780619
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Engagement of specific innate immune signaling pathways during Porphyromonas gingivalis induced chronic inflammation and atherosclerosis.
    Gibson FC; Ukai T; Genco CA
    Front Biosci; 2008 Jan; 13():2041-59. PubMed ID: 17981690
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inflammation and atherosclerosis: the role of TNF and TNF receptors polymorphisms in coronary artery disease.
    Sbarsi I; Falcone C; Boiocchi C; Campo I; Zorzetto M; De Silvestri A; Cuccia M
    Int J Immunopathol Pharmacol; 2007; 20(1):145-54. PubMed ID: 17346438
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Toll-like receptor-mediated inflammation markers are strongly induced in heart tissue in patients with cardiac disease under both ischemic and non-ischemic conditions.
    Rotter Sopasakis V; Sandstedt J; Johansson M; Lundqvist A; Bergström G; Jeppsson A; Mattsson Hultén L
    Int J Cardiol; 2019 Oct; 293():238-247. PubMed ID: 31230935
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of Toll-like receptors in infection and immunity: clinical implications.
    Cristofaro P; Opal SM
    Drugs; 2006; 66(1):15-29. PubMed ID: 16398566
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treating atherosclerosis: the potential of Toll-like receptors as therapeutic targets.
    Cole JE; Mitra AT; Monaco C
    Expert Rev Cardiovasc Ther; 2010 Nov; 8(11):1619-35. PubMed ID: 21090937
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.